Preferred Label : Vesigenurtucel-L;
NCIt definition : An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory
form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc
domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration
of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig
along with its chaperoned tumor associated antigens (TAAs). This enhances antigen
cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to
the induction of a potent CTL response against the TAAs on the endogenous bladder
cancer cells. This vaccine also induces a memory T cell response that could fight
recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum
(ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows
for gp96, normally an ER-resident chaperone peptide, to be released from cells.;
UNII : 9IE620X9FY;
Molecule name : HS-410;
NCI Metathesaurus CUI : CL458366;
Origin ID : C113653;
UMLS CUI : C5235372;
Semantic type(s)
- concept_is_in_subset
